Allergan Aesthetics has secured CE marking for Boey (trenibotulinumtoxinE), positioning it as the first and only rapid-onset, short-duration neurotoxin approved in Europe for glabellar frown lines. The product's mechanism—faster diffusion kinetics and a narrower therapeutic window—differentiates it from established competitors like Botox and Dysport, which typically require 3–7 days for full effect.
Boey's clinical profile targets a specific market segment: patients seeking quicker cosmetic results and practitioners managing toxin-related complications or seeking alternative dosing strategies. The shorter duration (expected 8–10 weeks versus 12+ for traditional formulations) creates higher re-treatment frequency, which carries both revenue and patient-retention implications for practices.